Shutdown Grabs Headlines, but Sequestration Does Real Damage
As NIH researchers are preparing to return to their laboratories, Alzheimer's researchers warn about the greater consequences of cutting already limited resources.
294 RESULTS
Sort By:
As NIH researchers are preparing to return to their laboratories, Alzheimer's researchers warn about the greater consequences of cutting already limited resources.
Conventional wisdom says that excess excitation promotes degeneration of motor neurons in ALS, but a new study suggests excitability could be a good thing.
Clinical trials could prove the value of amyloid scans to health insurers.
An inhibitor of a cellular stress response prevents neurodegeneration in mice infected with prion protein, and might have potential in other neurodegenerative diseases.
A mouse study suggests it may be possible to co-opt the liver to boost expression of neurotrophins in the brain.
A new study proposes microtubule-chopping enzymes as the missing link in the cascade of pathology leading from Aβ to tau to neuronal death.
People who carry the Huntington’s gene develop progressively abnormal brain metabolism a decade or more before diagnosis.
The Alzheimer’s Disease Neuroimaging Initiative has released whole genome sequences from 809 study volunteers.
Interested in Parkinson's? Apply for access to data and tissue samples, and funds to study them, from the Michael J. Fox Foundation.
By tracking Alzheimer’s research funding internationally, a new database could help sponsors coordinate research efforts.
In the first study of its kind, researchers found a surprisingly low incidence of Lewy body dementias in a U.S. population.
A new RNA interference therapy for amyotrophic lateral sclerosis has some success in mice and monkeys.
Advances in RNA sequencing are shedding light on gene regulation and helping scientists make sense of data from genome-wide association studies.
Rare mutations in the ADAM10 gene make a genetic case for the amyloid cascade as a cause of late onset Alzheimer's disease.
What’s better for future treatment of Parkinson’s: patient-derived or banked iPSCs? In comparison, patient’s own come out on top.